NuVasive’s Q3 Earnings Hit By COVID-19, Staff Shortage; Cuts FY21 Guidance
NuVasive Inc (NASDAQ:NUVA) reported Q3 net sales of $270.8 million, an 8.3% decrease on a reported and constant currency basis,…
Needham Maintains Buy on NuVasive, Lowers Price Target to $64
Needham analyst David Saxon maintains NuVasive (NASDAQ:NUVA) with a Buy and lowers the price target from $73 to $64.
NuVasive: Q3 Earnings Insights
NuVasive (NASDAQ:NUVA) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Needham Maintains Buy on NuVasive, Lowers Price Target to $73
Needham analyst David Saxon maintains NuVasive (NASDAQ:NUVA) with a Buy and lowers the price target from $80 to $73.
NuVasive Announces First Commercial Cases Utilizing The Pulse Platform
NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced Drs. Michael Kachmann and
NuVasive Simplify Cervical Disc Data Published In International Journal Of Spine Surgery
NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify®